↓ Skip to main content

Adipose Mesenchymal Stromal Cell-Based Therapy for Severe Osteoarthritis of the Knee: A Phase I Dose-Escalation Trial

Overview of attention for article published in Stem Cells Translational Medicine, May 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#6 of 1,608)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
66 news outlets
blogs
2 blogs
twitter
12 X users
facebook
6 Facebook pages
googleplus
3 Google+ users

Citations

dimensions_citation
393 Dimensions

Readers on

mendeley
363 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Adipose Mesenchymal Stromal Cell-Based Therapy for Severe Osteoarthritis of the Knee: A Phase I Dose-Escalation Trial
Published in
Stem Cells Translational Medicine, May 2016
DOI 10.5966/sctm.2015-0245
Pubmed ID
Authors

Yves-Marie Pers, Lars Rackwitz, Rosanna Ferreira, Oliver Pullig, Christophe Delfour, Frank Barry, Luc Sensebe, Louis Casteilla, Sandrine Fleury, Philippe Bourin, Danièle Noël, François Canovas, Catherine Cyteval, Gina Lisignoli, Joachim Schrauth, Daniel Haddad, Sophie Domergue, Ulrich Noeth, Christian Jorgensen, on behalf of the ADIPOA Consortium

X Demographics

X Demographics

The data shown below were collected from the profiles of 12 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 363 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Unknown 362 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 54 15%
Researcher 48 13%
Student > Master 38 10%
Student > Ph. D. Student 37 10%
Other 25 7%
Other 55 15%
Unknown 106 29%
Readers by discipline Count As %
Medicine and Dentistry 103 28%
Biochemistry, Genetics and Molecular Biology 47 13%
Agricultural and Biological Sciences 27 7%
Engineering 11 3%
Nursing and Health Professions 10 3%
Other 47 13%
Unknown 118 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 536. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 August 2017.
All research outputs
#46,666
of 25,837,817 outputs
Outputs from Stem Cells Translational Medicine
#6
of 1,608 outputs
Outputs of similar age
#924
of 351,931 outputs
Outputs of similar age from Stem Cells Translational Medicine
#3
of 62 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,608 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.4. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,931 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.